Loading asset research
AgomAb Therapeutics NV American Depositary Shares
AGMBNasdaq · USD · StocksQuote as of · Exchange session not verified$12.98
-6.89%
Today
AGMB
Loading 1D prices…
Market cap
$643.2M
Volume
196.7K
52w high
$17.8252w low
$8.75Company profile
AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Antwerp, United States
Employees
62
Fiscal year end
1231
CIK
2020932
Session & valuation
Open$14.00
Previous close$13.94
Day high$14.10
Day low$12.96
30-day avg. volume147.7K
Outstanding shares34.2M
Diluted EPS-$1.28
Latest annual period
P/E (trailing)-10.11
P/E (forward)-6.31
Price / book4.95
Beta—
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| VALNValneva SE American Depositary Shares | $631.5M | — | — | -$1.36 | -0.45% | Buy |
| ALLOAllogene Therapeutics Inc. Common Stock | $615M | $0.00 | — | -$0.87 | +1.14% | Buy |
| PROKProKidney Corp. Class A Ordinary Shares | $718.5M | $893K | -7725.20% | -$0.52 | -1.63% | Hold |
| AURAAura Biosciences Inc. Common Stock | $725.4M | $0.00 | — | -$1.76 | +0.29% | Buy |
| FDMT4D Molecular Therapeutics Inc. Common Stock | $727.6M | $85.2M | -164.43% | -$2.42 | -2.37% | Buy |